Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2018 | Identifying non-invasive biomarker assays for lung cancer: what is an appropriate control group?

Robert Rintoul • 25 Jan 2018
BTOG 2018
Lung Cancer Non-Small Cell Lung Cancer Small Cell Lung Cancer

A non-invasive biomarker assay to detect lung cancer would be ideal; avoiding needless biopsies and providing another step of diagnostic validation. However, finding the optimal control group to identify these signatures is not easy, as explained here by Robert Rintoul, PhD, FRCP, of the Cancer Research UK Cambridge Institute, Cambridge, UK. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

More from Robert Rintoul

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
8:53
The targeted lung health check (TLHC) program in the UK
Robert Rintoul • 28 Apr 2023

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals